Tags

Type your tag names separated by a space and hit enter

Phosphodiesterase inhibitors. Do the risks outweight the benefits?
Drug Saf. 1993 Dec; 9(6):404-9.DS

Abstract

Despite the justifiable concern about the use of oral cyclic adenosine monophosphate phosphodiesterase (cAMP PDE) inhibitors, the intravenous preparations are clearly effective in the treatment of acute heart failure, whether it occurs de novo or complicating chronic congestive heart failure (CHF), and in low output states following cardiac surgery. There are no grounds to curtail their use in these areas, though any advantages over conventional agents such as dobutamine need further investigation with regard to end-points other than haemodynamic parameters. The long term use of oral cAMP PDE inhibitors in the treatment of chronic CHF should remain restricted by the increase in mortality now confirmed in severe CHF. However, in view of the distressing nature of the condition there remain subgroups of patients in whom the benefits may outweight the risks.

Authors+Show Affiliations

Division of Cardiovascular Medicine, University Hospital, Nottingham, England.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

8129862

Citation

Andrews, R, and A J. Cowley. "Phosphodiesterase Inhibitors. Do the Risks Outweight the Benefits?" Drug Safety, vol. 9, no. 6, 1993, pp. 404-9.
Andrews R, Cowley AJ. Phosphodiesterase inhibitors. Do the risks outweight the benefits? Drug Saf. 1993;9(6):404-9.
Andrews, R., & Cowley, A. J. (1993). Phosphodiesterase inhibitors. Do the risks outweight the benefits? Drug Safety, 9(6), 404-9.
Andrews R, Cowley AJ. Phosphodiesterase Inhibitors. Do the Risks Outweight the Benefits. Drug Saf. 1993;9(6):404-9. PubMed PMID: 8129862.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Phosphodiesterase inhibitors. Do the risks outweight the benefits? AU - Andrews,R, AU - Cowley,A J, PY - 1993/12/1/pubmed PY - 1993/12/1/medline PY - 1993/12/1/entrez SP - 404 EP - 9 JF - Drug safety JO - Drug Saf VL - 9 IS - 6 N2 - Despite the justifiable concern about the use of oral cyclic adenosine monophosphate phosphodiesterase (cAMP PDE) inhibitors, the intravenous preparations are clearly effective in the treatment of acute heart failure, whether it occurs de novo or complicating chronic congestive heart failure (CHF), and in low output states following cardiac surgery. There are no grounds to curtail their use in these areas, though any advantages over conventional agents such as dobutamine need further investigation with regard to end-points other than haemodynamic parameters. The long term use of oral cAMP PDE inhibitors in the treatment of chronic CHF should remain restricted by the increase in mortality now confirmed in severe CHF. However, in view of the distressing nature of the condition there remain subgroups of patients in whom the benefits may outweight the risks. SN - 0114-5916 UR - https://www.unboundmedicine.com/medline/citation/8129862/Phosphodiesterase_inhibitors__Do_the_risks_outweight_the_benefits L2 - https://dx.doi.org/10.2165/00002018-199309060-00003 DB - PRIME DP - Unbound Medicine ER -